Company / Return on Equity (ROE)
Bicara Therapeutics Inc. Return on Equity (ROE) History
FY2024-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-13.8%
FY2024
5-year range
-13.8% / -13.8%
FY2024-FY2024
Trend
-
vs FY2023
Sector context
#67 of 190
Health Care
What the data says
At -13.8%, Bicara Therapeutics Inc.'s return on equity (roe) ranks #67 of 190 in the Health Care sector.
Based on SEC 10-K filings.
-13.8% in FY2024.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#67 of 190 in Health CareTop 35% of 190This company -13.8% Sector average -50.4%
▼
+72.6% above sector average
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 11.58 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -13.8% | - |
| FY2023 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026